USRE33963E - Solid rapidly released medicament preparations containing dihydropyridines, and processes for their preparation - Google Patents

Solid rapidly released medicament preparations containing dihydropyridines, and processes for their preparation Download PDF

Info

Publication number
USRE33963E
USRE33963E US07/647,611 US64761191A USRE33963E US RE33963 E USRE33963 E US RE33963E US 64761191 A US64761191 A US 64761191A US RE33963 E USRE33963 E US RE33963E
Authority
US
United States
Prior art keywords
weight
solid
parts
nifedipine
pvp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/647,611
Inventor
Ahmed Hegasy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19813142853 external-priority patent/DE3142853A1/en
Priority claimed from DE19823205399 external-priority patent/DE3205399A1/en
Application filed by Bayer AG filed Critical Bayer AG
Priority to US07/647,611 priority Critical patent/USRE33963E/en
Application granted granted Critical
Publication of USRE33963E publication Critical patent/USRE33963E/en
Assigned to BAYER HEALTHCARE AG reassignment BAYER HEALTHCARE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAYER AKTIENGESELLSCHAFT
Anticipated expiration legal-status Critical
Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BAYER HEALTHCARE AG
Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT A CHANGE OF NAME WAS RECORDED ON AUGUST 28, 2009 AT REEL/FRAME 023148/0924. THE ADDRESS SHOULD ALSO HAVE BEEN CHANGE FROM LEVERKUSEN GERMANY 51368 TO BERLIN, GERMANY 13353 Assignors: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Definitions

  • the present invention relates to certain novel special rapidly absorbable solid medicament preparations which contain dihydropyridines and polyvinylpyrrolidone, and to processes for their preparation.
  • Nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-pyridine-3,5-dicarboxylate) is a known active compound from the substance class of the dihydropyridines, which affects the circulation (see British Patent Specification No. 1,173,862). Owing to its extreme sensitivity to light and its extremely low solubility in aqueous media, a number of difficulties occur in the pharmaceutical preparation of special medicaments, as is evident from numerous patent applications and patents for special formations of this active compound.
  • U.S. Pat. No. 3,784,684 relates, for example, to special gelatine bitable capsules which contain nifedipine in dissolved form, in order advantageously to utilise the coronary action of nifedipine.
  • British Patent Specification No. 1,456,618 describes and claims solid medicament preparations which are intended to ensure good bio-availability of the nifedipine.
  • coprecipitates are prepared by dissolving nifedipine and PVP in organic solvents and subsequently evaporating the solvent to obtain a glassy mass (see DEOS (German Published Specification) No. 2,822,882).
  • nifedipine and PVP inorganic solvents
  • evaporation of the organic solvent can be carried out industrially only at great expense, since the PVP mass binds the organic solvent strongly and becomes very viscous shortly before drying.
  • a voluminous foamy mass is formed which is very viscous shortly before the end of the drying procedure, can no longer be stirred, and is difficult to process further.
  • auxiliaries which may be chosen are very limited, in particular for the production of tablets, because PVP simultaneously acts as a binder, and the disintegration of the tablets or capsules is hindered by the presence of large amounts of PVP (30-100 mg per tablet or capsule).
  • Nimodipine (1,4-dihydro-2,6-dimethyl-4-(3'-nitrophenyl)-pyridine 3-methoxyethyl ester 5-isopropyl ester) is likewise a known dihydropyridine with a cerebral action (see DOS (German Published Specification) No. 2,815,578). This compound also is difficult to process to give pharmaceutical preparation forms, owing to its physico-chemical properties. Nimodipine has, for example, a substantially poorer solubility than nifedipine in aqueous media.
  • the present invention relates to new solid rapidly released preparations containing dihydropyridines, and processes for their preparation, which no longer have these disadvantages of the preparations known hitherto.
  • rapidly absorbable, solid medicament preparations with a uniform active compound content comprising 1 part by weight of dihydropyridine as active compound, 2.0 to 6.0 parts by weight of PVP having a mean molecular weight of 15,000 to 50,000, and absorptive excipients consisting of from 3.5 to 15 parts by weight of cellulose, 0.25 to 4.0 parts by weight of starch and 0.25 to 4.0 parts by weight of crosslinked insoluble PVPP, and comprising if appropriate, further formulation auxiliaries and/or excipients.
  • PVPP cross-linked insoluble polyvinylpyrrolidone
  • Polyplasdone XL® from GAF Corp., New York, N.Y. USA or KOLLIDONE CL® from BASF, Ludwigshafen, Germany.
  • These solid medicament preparations are prepared by a process in which 1 part by weight of dihydropyridine and 2 to 6 parts by weight of PVP are dissolved in a small amount of organic solvent in which the two solid constituents are just soluble, and this solution is granulated with 4 to 23 parts by weight, preferably with 5.25 to 17 parts by weight, of the abovementioned excipients, and these granules are then processed further, if desired, with further formulation auxiliaries and/or excipients to give solid medicament preparations.
  • organic solvents C 1 -C 3 -alkanols; C 1 -C 2 -dialkyl ketones; and chlorinated alkanes having 1-2 carbon atoms.
  • organic solvents include ethanol, acetone, methylene chloride and chloroform, and in particular mixtures of these solvents. They are preferably employed in an amount of 2 to 20, in particular of 8 to 16, parts by weight, relative to the dihydropyridine.
  • a .[.power.]. .Iadd.powder .Iaddend.mixture of 4 to 12 parts by weight of cellulose, 0.25 to 2.0 parts by weight of starch and 1 to 3 parts by weight of crosslinked insoluble PVPP is particularly suitable as the said adsorptive excipient.
  • Preferred preparations according to the present invention are those in which the relative standard deviation of the active compound content is at most 2.5% and 50% of the active compound is released in less than 30 minutes; especially those in which the active compound is nifedipine 50% of which is released in less than 15 minutes.
  • solid medicament preparations tablets, pills, dragees, granules, powders, capsules and sachets.
  • the granules obtained by the process according to the invention and consisting of the powder mixture wetted with active compound/PVP solution can, without problems, be dried, sieved, processed further, mixed with other auxiliaries and excipients and pressed to give tablets.
  • tablets were prepared, according to Examples A to F, by conventional methods in which a solid coprecipitate of nifedipine and PVP was first prepared by evaporating off the solvent, and these solid granules were then mixed with customary auxiliaries and excipients, and processed further to give solid tablets.
  • the coprecipitate of nifedipine and PVP or of nimodipine and PVP was not isolated but was granulated as a solution with a mixture of solid excipients, and these granules were then pressed in the customary manner to give tablets.
  • Example 1 The mixtures of Examples A to F and Example 1 relative to the preparation of 10,000 tablets each. Examples 2 to 4 account for 15,000 tablets each.
  • coprecipitates prepared in the same manner as in A were brought, via an oscillating sieve, to a maximum particle size of 0.8 mm in the case of Example B or 0.6 mm in the case of Example C, and were then processed further, in the same manner as in Example A, to give tablets.
  • coprecipitate prepared analogously to Example A was comminuted by means of a hammer mill and then processed further, as in Example A, to give tablets.
  • a coprecipitate prepared analogously to Example E was mixed directly with the mixture of cellulose and starch, was granulated with the starch paste (that is to say in an aqueous medium), and was then pressed to give tablets, analogously to Example E. Although the tablets prepared in this manner possessed an improved content uniformity, they gave unsatisfactory release values.
  • nifedipine and 400 g of PVP 25 were dissolved in 1,800 of methylene chloride.
  • 1,050 g of cellulose, 200 g of starch and 100 g of insoluble PVPP were mixed in the dry state and granulated with the nifedipine/PVP solution.
  • the moist granules obtained were dried and sieved, 145 g of insoluble PVPP, 200 g of starch and 4 g of magnesium stearate were then added, the ingredients were mixed, and this mixture was pressed to give tablets of 220 mg. These tablets were distinguished by a very good content uniformity and advantageous release.
  • Example 2 Analogously to Example 1, 150 g of nifedipine and 600 g of PVP 25 were dissolved in 1,800 g of methylene chloride, and this solution was granulated directly with a mixture of 1,575 g of microcrystalline cellulose ("Avicel") and 600 g of corn starch. After the granules had been dried and sieved, they were mixed with 6 g of magnesium stearate and 369 g of insoluble PVPP, and the mixture was pressed to give tablets weighing 220 mg.
  • Avicel microcrystalline cellulose
  • Example 2 Analogously to Example 2, 150 g of nifedipine and 600 g of PVP 25 were dissolved in 2,200 g of methylene chloride. The solution was granulated for granulating a mixture of 1,575 g of microcrystalline cellulose 600 g of corn starch and 300 g of insoluble PVPP. After the granules had been dried and sieved, they were mixed with 6 g of magnesium stearate and 69 g of insoluble PVPP, and the mixture was pressed to give tablets weighing 220 mg.
  • nifedipine and 600 g of PVP 25 were dissolved in 2,100 g of methylene chloride. This solution was used for granulating a mixture of 1,575 g of microcrystalline cellulose, 600 g of corn starch and 150 g of insoluble PVPP. After the granules had been dried and sieved, they were mixed with 66 g of magnesium stearate and 219 g of insoluble PVPP, and the mixture was pressed to give tablets weighing 220 mg.
  • nifedipine 1 kg of nifedipine and 4 kg of PVP 25 were dissolved in 7 kg of acetone.
  • the solution was used for granulating a mixture of 10.5 kg of microcrystalline cellulose ("Avicel"), 2 kg of starch and 1 kg of insoluble PVPP.
  • the mass was dried in vacuo, sieved, and mixed with 1.46 kg of insoluble PVPP, 2 kg of starch and 0.04 kg of magnesium stearate.
  • the mixture was pressed to give tablets weighing 220 mg and having a diameter of 9 mm.
  • 20 kg of tablets were sprayed with a suspension of 0.3 kg of hydroxypropylmethylcellulose, 0.1 kg of polyethylene glycol 4000, 0.09 kg of titanium dioxide and 0.01 kg of red iron oxide in 6.17 kg of water.
  • nimodipine 0.6 kg of nimodipine and 1.5 kg of PVP 25 were dissolved in 1.4 kg of acetone. The solution was used for granulating a mixture of 2.85 kg of microcrystalline cellulose, 0.150 kg of starch and 0.6 kg of insoluble PVPP. The mass was dried in vacuo, sieved, and mixed with 0.288 kg of insoluble PVPP, 0.566 kg of starch and 0.011 kg of magnesium stearate. The mixture was pressed to give tablets weighing 330 mg and having a diameter of 10 mm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Solid dihydropyridines, e.g. nifedipine and nimodipine preparations having a maximum standard deviation of the active compound content of 3% contain 1 part by weight of nifedipine, 2 to 6 parts by weight of PVP with a mean molecular weight of 15,000 to 50,000, 3.5 to 15 parts by weight of cellulose, 0.25 to 4 parts by weight of starch and 0.5 to 4 parts by weight of cross-linked insoluble PVPP, and, if appropriate, one or more further pharmaceutical auxiliaries and excipients. These preparations show a good release of dihydropyridine with good content uniformity.

Description

This is a continuation of application Ser. No. 728,123, filed Apr. 29, 1985 (now abandoned) which in turn is a continuation of application Ser. No. 433,570 filed Oct. 8,1982 (now abandoned).
The present invention relates to certain novel special rapidly absorbable solid medicament preparations which contain dihydropyridines and polyvinylpyrrolidone, and to processes for their preparation.
Nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-pyridine-3,5-dicarboxylate) is a known active compound from the substance class of the dihydropyridines, which affects the circulation (see British Patent Specification No. 1,173,862). Owing to its extreme sensitivity to light and its extremely low solubility in aqueous media, a number of difficulties occur in the pharmaceutical preparation of special medicaments, as is evident from numerous patent applications and patents for special formations of this active compound.
U.S. Pat. No. 3,784,684 relates, for example, to special gelatine bitable capsules which contain nifedipine in dissolved form, in order advantageously to utilise the coronary action of nifedipine.
British Patent Specification No. 1,456,618 describes and claims solid medicament preparations which are intended to ensure good bio-availability of the nifedipine.
DE-OS (German Published Specification) No. 2,822,882 likewise describes solid medicament preparations in which the poor solubility of nifedipine is to be compensated by the use of certain solvents and surface-active substances.
In European Published Patent Application No. 1,247, it is also intended to improve the absorbability of nifedipine by the use of polyethylene glycol (PEG) and certain porous excipients. In this application, it is also stated that the poor solubility of nifedipine can be compensated by the formation of coprecipitates of nifedipine and polyvinylpyrrolidone (PVP), in which coprecipitates the nifedipine is present in amorphous form.
These coprecipitates are prepared by dissolving nifedipine and PVP in organic solvents and subsequently evaporating the solvent to obtain a glassy mass (see DEOS (German Published Specification) No. 2,822,882). Such an evaporation of the organic solvent can be carried out industrially only at great expense, since the PVP mass binds the organic solvent strongly and becomes very viscous shortly before drying. A voluminous foamy mass is formed which is very viscous shortly before the end of the drying procedure, can no longer be stirred, and is difficult to process further. A further disadvantage in the use of customary PVP coprecipitates in the production of tablets is the fact that this coprecipitate can only be mixed with other auxiliaries but can no longer be directly granulated with aqueous solutions. However, such a simple mixture of the PVP coprecipitate with other auxiliaries tends to separate during further mechanical processing, for example to give tablets or during introduction into capsules. This can finally lead to medicament preparations with very variable active compound contents in the individual tablets or capsules (deficient "content uniformity"), which is extremely undesirable in the case of a highly active substance such as nifedipine. Moreover, the additional auxiliaries which may be chosen are very limited, in particular for the production of tablets, because PVP simultaneously acts as a binder, and the disintegration of the tablets or capsules is hindered by the presence of large amounts of PVP (30-100 mg per tablet or capsule).
Nimodipine (1,4-dihydro-2,6-dimethyl-4-(3'-nitrophenyl)-pyridine 3-methoxyethyl ester 5-isopropyl ester) is likewise a known dihydropyridine with a cerebral action (see DOS (German Published Specification) No. 2,815,578). This compound also is difficult to process to give pharmaceutical preparation forms, owing to its physico-chemical properties. Nimodipine has, for example, a substantially poorer solubility than nifedipine in aqueous media.
The present invention relates to new solid rapidly released preparations containing dihydropyridines, and processes for their preparation, which no longer have these disadvantages of the preparations known hitherto.
According to the present invention there are provided rapidly absorbable, solid medicament preparations with a uniform active compound content, the relative standard deviation of which is at most 3%, preferably at most 2.5%, comprising 1 part by weight of dihydropyridine as active compound, 2.0 to 6.0 parts by weight of PVP having a mean molecular weight of 15,000 to 50,000, and absorptive excipients consisting of from 3.5 to 15 parts by weight of cellulose, 0.25 to 4.0 parts by weight of starch and 0.25 to 4.0 parts by weight of crosslinked insoluble PVPP, and comprising if appropriate, further formulation auxiliaries and/or excipients. The abbreviation "PVPP" used herein stands for cross-linked insoluble polyvinylpyrrolidone, such as Polyplasdone XL® from GAF Corp., New York, N.Y. USA or KOLLIDONE CL® from BASF, Ludwigshafen, Germany.
These solid medicament preparations are prepared by a process in which 1 part by weight of dihydropyridine and 2 to 6 parts by weight of PVP are dissolved in a small amount of organic solvent in which the two solid constituents are just soluble, and this solution is granulated with 4 to 23 parts by weight, preferably with 5.25 to 17 parts by weight, of the abovementioned excipients, and these granules are then processed further, if desired, with further formulation auxiliaries and/or excipients to give solid medicament preparations.
The following may preferably be mentioned as organic solvents: C1 -C3 -alkanols; C1 -C2 -dialkyl ketones; and chlorinated alkanes having 1-2 carbon atoms. Specific examples include ethanol, acetone, methylene chloride and chloroform, and in particular mixtures of these solvents. They are preferably employed in an amount of 2 to 20, in particular of 8 to 16, parts by weight, relative to the dihydropyridine.
A .[.power.]. .Iadd.powder .Iaddend.mixture of 4 to 12 parts by weight of cellulose, 0.25 to 2.0 parts by weight of starch and 1 to 3 parts by weight of crosslinked insoluble PVPP is particularly suitable as the said adsorptive excipient.
Preferred preparations according to the present invention are those in which the relative standard deviation of the active compound content is at most 2.5% and 50% of the active compound is released in less than 30 minutes; especially those in which the active compound is nifedipine 50% of which is released in less than 15 minutes.
The following may preferably be mentioned as customary auxiliaries and excipients which can be used for further processing to give solid medicament preparations: lactose, powdered sugar, mannitol, glycocoll and calcium carbonate.
The following may preferably be mentioned as solid medicament preparations: tablets, pills, dragees, granules, powders, capsules and sachets.
It could not be foreseen that the medicament preparations thus obtained would possess very good bioavailability and at the same time a good content uniformity. The granules obtained by the process according to the invention and consisting of the powder mixture wetted with active compound/PVP solution can, without problems, be dried, sieved, processed further, mixed with other auxiliaries and excipients and pressed to give tablets.
In view of the numerous attempts, known from the prior art, to prepare suitable medicament preparations containing dihydropyridine, it could not be foreseen that new and valuable medicament preparations which contain these active compounds, which are distinguished by good bio-availability, and the active compound content of which only has a maximum standard deviation of 3%, preferably of 2.5%, would be obtained by the process according to the invention, which process can be carried out readily and without technical effort (see the textbook: Pharmazeutische Technologie (Pharmaceutical Technology), published by Sucker, Fuchs and Speises, page 32 to 37, and U.S. Pharmacopoea XX, page 955 to 957).
To demonstrate the advantageous properties of the best preparations prepared according to the invention, tablets were prepared, according to Examples A to F, by conventional methods in which a solid coprecipitate of nifedipine and PVP was first prepared by evaporating off the solvent, and these solid granules were then mixed with customary auxiliaries and excipients, and processed further to give solid tablets. In contrast, in Examples 1 to 8 according to the invention, the coprecipitate of nifedipine and PVP or of nimodipine and PVP was not isolated but was granulated as a solution with a mixture of solid excipients, and these granules were then pressed in the customary manner to give tablets.
The following table shows that the solid formulations according to the invention are very rapidly and completely absorbed (good release) and at the same time exhibit only a very low relative standard deviation of the active compound content (good content uniformity).
                                  TABLE                                   
__________________________________________________________________________
                             Examples according to                        
          Examples according to known methods                             
                             the invention                                
Example No.                                                               
          A  B  C  D  E   F  1   2   3   4                                
__________________________________________________________________________
Standard deviation                                                        
          1.7%                                                            
             1.0%                                                         
                1.1%                                                      
                   1.7%                                                   
                      --  -- 1.0%                                         
                                 0.7%                                     
                                     0.7%                                 
                                         0.8%                             
of the tablet                                                             
weights                                                                   
Deviation of the                                                          
          8.86-                                                           
             8.04-                                                        
                8.75-                                                     
                   8.44-                                                  
                      10.01-                                              
                          9.55-                                           
                             10.03-                                       
                                 10.30-                                   
                                     10.49-                               
                                         9.98-                            
nifedipine con-                                                           
          10.12                                                           
             10.32                                                        
                10.15                                                     
                   9.65                                                   
                      10.83                                               
                          10.03                                           
                             10.31                                        
                                 10.55                                    
                                     10.81                                
                                         10.53                            
tent in mg in                                                             
individual                                                                
tablets (10                                                               
tablets)                                                                  
Standard deviation                                                        
          4.1%                                                            
             6.7%                                                         
                5.1%                                                      
                   4.7%                                                   
                      2.4%                                                
                          1.8%                                            
                             1.0%                                         
                                 0.774%                                   
                                     1.088%                               
                                         1.413%                           
of the nifedipine                                                         
content per                                                               
tablet                                                                    
Nifedipine release*                                                       
          appr.                                                           
             appr.                                                        
                appr.                                                     
                   appr.                                                  
                      <10'                                                
                          30'-40'                                         
                             <5' <10'                                     
                                     <10'                                 
                                         <10'                             
50% released after                                                        
          10'                                                             
             10'                                                          
                10'                                                       
                   10'                                                    
(minutes)                                                                 
__________________________________________________________________________
 *The release test is effected according to the USP Paddle method.
Examples of the preparation of solid nifedipine preparations according to known methods
The mixtures of Examples A to F and Example 1 relative to the preparation of 10,000 tablets each. Examples 2 to 4 account for 15,000 tablets each.
EXAMPLE A
100 g of nifedipine and 400 g of PVP 25 (mean molecular weight 25,000) were dissolved in 1,500 g of methylene chloride. When the solvent was evaporated, a very viscous mass which could not be stirred was initially formed, and this mass became a foamy glass mass after some time. This coprecipitate was brought to a maximum particle size of 1.0 mm via an oscillating sieve. In a separate operation, granules were prepared from 1,050 g of microcrystalline cellulose ("Avicel"--Trade Mark), 350 g of corn starch and 50 g of corn starch made into a paste with boiling water. These granules were mixed with 500 g of the nifedipine coprecipitate, with 4 g of magnesium stearate and 246 g of insoluble cross-linked PVP (e.g. Plasdone XL-Trade Mark, or Kollidon CL-Trade Mark). Tablets having a weight of 220 mg and a mean nifedipine content of 10 mg were prepared from this mixture.
EXAMPLES B AND C
The coprecipitates prepared in the same manner as in A were brought, via an oscillating sieve, to a maximum particle size of 0.8 mm in the case of Example B or 0.6 mm in the case of Example C, and were then processed further, in the same manner as in Example A, to give tablets.
EXAMPLE D
The coprecipitate prepared analogously to Example A was comminuted by means of a hammer mill and then processed further, as in Example A, to give tablets.
EXAMPLE E
100 g of nifedipine and 400 g of PVP 25 were dissolved in 1,200 g of methylene chloride, and the solution was dried in vacuo. The coprecipitate obtained was mixed directly with granules which had been prepared from 100 g of cellulose, 450 g of starch and 50 g of starch made into a paste with boiling water, and with 5 g of magnesium stearate, 195 g of starch and 200 g of insoluble polyvinylpyrrolidone, and this mixture was then pressed to give tablets weighing 240 mg.
EXAMPLE F
A coprecipitate prepared analogously to Example E was mixed directly with the mixture of cellulose and starch, was granulated with the starch paste (that is to say in an aqueous medium), and was then pressed to give tablets, analogously to Example E. Although the tablets prepared in this manner possessed an improved content uniformity, they gave unsatisfactory release values.
The following Examples illustrate medicaments and a process for their production according to the present invention.
EXAMPLE 1
100 g of nifedipine and 400 g of PVP 25 were dissolved in 1,800 of methylene chloride. In a granulating apparatus, 1,050 g of cellulose, 200 g of starch and 100 g of insoluble PVPP were mixed in the dry state and granulated with the nifedipine/PVP solution. The moist granules obtained were dried and sieved, 145 g of insoluble PVPP, 200 g of starch and 4 g of magnesium stearate were then added, the ingredients were mixed, and this mixture was pressed to give tablets of 220 mg. These tablets were distinguished by a very good content uniformity and advantageous release.
EXAMPLE 2
Analogously to Example 1, 150 g of nifedipine and 600 g of PVP 25 were dissolved in 1,800 g of methylene chloride, and this solution was granulated directly with a mixture of 1,575 g of microcrystalline cellulose ("Avicel") and 600 g of corn starch. After the granules had been dried and sieved, they were mixed with 6 g of magnesium stearate and 369 g of insoluble PVPP, and the mixture was pressed to give tablets weighing 220 mg.
EXAMPLE 3
Analogously to Example 2, 150 g of nifedipine and 600 g of PVP 25 were dissolved in 2,200 g of methylene chloride. The solution was granulated for granulating a mixture of 1,575 g of microcrystalline cellulose 600 g of corn starch and 300 g of insoluble PVPP. After the granules had been dried and sieved, they were mixed with 6 g of magnesium stearate and 69 g of insoluble PVPP, and the mixture was pressed to give tablets weighing 220 mg.
EXAMPLE 4
150 g of nifedipine and 600 g of PVP 25 were dissolved in 2,100 g of methylene chloride. This solution was used for granulating a mixture of 1,575 g of microcrystalline cellulose, 600 g of corn starch and 150 g of insoluble PVPP. After the granules had been dried and sieved, they were mixed with 66 g of magnesium stearate and 219 g of insoluble PVPP, and the mixture was pressed to give tablets weighing 220 mg.
EXAMPLE 5
The following amounts are calculated for the production of 100,000 tablets, each containing 10 mg of nifedipine: 1 kg of nifedipine and 4 kg of PVP 25 were dissolved in 7 kg of acetone. The solution was used for granulating a mixture of 10.5 kg of microcrystalline cellulose ("Avicel"), 2 kg of starch and 1 kg of insoluble PVPP. The mass was dried in vacuo, sieved, and mixed with 1.46 kg of insoluble PVPP, 2 kg of starch and 0.04 kg of magnesium stearate. The mixture was pressed to give tablets weighing 220 mg and having a diameter of 9 mm. 20 kg of tablets were sprayed with a suspension of 0.3 kg of hydroxypropylmethylcellulose, 0.1 kg of polyethylene glycol 4000, 0.09 kg of titanium dioxide and 0.01 kg of red iron oxide in 6.17 kg of water.
EXAMPLE 6
The following amounts are calculated for the production of 250,000 tablets, each contianing 20 mg of nifedipine: 5 kg of nifedipine and 20 kg of PVP 25 were dissolved in a mixture of.35 kg of acetone and 10 kg of methylene chloride. The solution was used for granulating a mixture of 52.5 kg of microcrystalline cellulose, 10 kg of starch and 5 kg of insoluble PVPP. After the granules had been dried in vacuo and sieved, they were admixed with 7.3 kg of insoluble PVPP, 10 kg of starch and 0.2 kg of magnesium stearate. The mixture was pressed to give tablets weighing 440 mg. 100 kg of tablets were coated by spraying with a suspension of 1.5 kg of hydroxypropylmethylcellulose, 0.5 kg of PEG 4000, 0.4 kg of titanium dioxide, 0.1 kg of red iron oxide and 30.83 kg of water.
EXAMPLE 7
The following amounts are calculated for the production of 20,000 tablets, each containing 30 mg of nimodipine: 0.6 kg of nimodipine and 1.5 kg of PVP 25 were dissolved in 1.4 kg of acetone. The solution was used for granulating a mixture of 2.85 kg of microcrystalline cellulose, 0.150 kg of starch and 0.6 kg of insoluble PVPP. The mass was dried in vacuo, sieved, and mixed with 0.288 kg of insoluble PVPP, 0.566 kg of starch and 0.011 kg of magnesium stearate. The mixture was pressed to give tablets weighing 330 mg and having a diameter of 10 mm. 6 kg of tablets were coated by spraying with a suspension of 0.225 kg of hydroxypropylmethylcellulose, 0.075 kg of polyethylene glycol 4000 and 0.075 kg of titanium dioxide in 4.625 kg of water. The analyses of the individual tablet content of nimodipine were between 29.78 mg and 31.18 mg, with a relative standard deviation of 1.156%.
EXAMPLE 8
A batch of 26.4 kg of tablet mixture, sufficient for 60,000 tablets, each containing 40 mg of nimodipine, was prepared in the following manner: 2.4 kg of nimodipine and 6.0 kg of PVP 25 were stirred in 5.76 kg of acetone until a clear viscous solution was present. 11.4 kg of microcrystalline cellulose, 0.6 kg of starch and 2.4 kg of insoluble PVPP were mixed in a granulating apparatus. The abovementioned solution containing nimodipine was then added. After this solution had been granulated with the powder constituents, the mass was dried in vacuo and then brought to a mean particle size of 1.0 mm diameter by sieving. For this purpose, 2.4 kg of starch, 1.152 kg of insoluble PVPP and 0.48 kg of magnesium stearate were mixed. Tablets having a weight of 440 mg were pressed from this mixture. 24 kg of these tablets were coated by spraying with a suspension of 0.54 kg of hydroxypropyl-methylcellulose, 0.18 kg of polyethylene glycol 4000 and 0.18 kg of titanium dioxide in 11.1 kg of water. The average content of nimodipine in the individual tablets as 40.5 mg. The relative standard deviation was 2.21%.

Claims (8)

What is claimed is:
1. A solid, rapidly absorbable preparation in unit dosage form comprising 1 part by weight of a dihydropyridine as an active compound, .[.0.2.]. .Iadd.2.0 .Iaddend.to 6.0 parts by weight of PVP having a mean molecular weight of 15,000 to 50,000, and a mixture of absorptive excipients comprising 3.5 to 15 parts by weight of cellulose, 0.25 to 4.0 parts by weight of starch, 0.25 to 4.0 parts by weight of crosslinked insoluble PVPP, said preparation provided by (a) coprecipitation of the dihydropyridine and the PVP, (b) granulation of the resultant coprecipitation without removal of the parent solution and (c) admixture with the absorptive excipients.
2. A solid, rapidly absorbable preparation according to claim 1 in the form of tablets, pills, dragees, granules, powders, capsules or sachets.
3. A solid rapidly absorbable preparation according to claim 1, wherein said dihydropyridine is nifedipine.
4. A solid, rapidly absorbable preparation according to claim 1, wherein said dihydropyridine is nimodipine.
5. A solid, rapidly absorbable preparation according to claim 1, wherein the active compound has a maximum relative standard deviation of 1.413% on a weight basis.
6. A solid, rapidly absorbable preparation according claim 1, wherein the absorptive excipients comprise a mixture of 4 to 12 parts by weight of cellulose, 0.25 to 2.0 parts by weight of starch and 1 to 3 parts by weight of crosslinked insoluble PVPP.
7. A solid, rapidly absorbable preparation according to claim 1, wherein 50% of said dihydropyridine is released in less than 15 minutes as measured by the USP paddle method.
8. A solid, rapidly absorbable preparation according to claim 1, which further comprises one or more excipients selected from the group consisting of lactose, powdered sugar, mannitol, glycocoll and calcium carbonate.
US07/647,611 1981-10-29 1991-01-28 Solid rapidly released medicament preparations containing dihydropyridines, and processes for their preparation Expired - Lifetime USRE33963E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/647,611 USRE33963E (en) 1981-10-29 1991-01-28 Solid rapidly released medicament preparations containing dihydropyridines, and processes for their preparation

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE3142853 1981-10-29
DE19813142853 DE3142853A1 (en) 1981-10-29 1981-10-29 Solid pharmaceutical compositions containing nifedipine and process for their production
DE19823205399 DE3205399A1 (en) 1982-02-16 1982-02-16 Solid, rapid-release pharmaceutical compositions with dihydropyridines and process for their production
DE3205399 1982-02-16
US07/647,611 USRE33963E (en) 1981-10-29 1991-01-28 Solid rapidly released medicament preparations containing dihydropyridines, and processes for their preparation

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US06728123 Continuation 1985-04-29
US06/864,677 Reissue US4882144A (en) 1981-10-29 1986-05-19 Solid, rapidly released medicament preparations containing dihydropyridines, and processes for their preparation

Publications (1)

Publication Number Publication Date
USRE33963E true USRE33963E (en) 1992-06-16

Family

ID=27189648

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/647,611 Expired - Lifetime USRE33963E (en) 1981-10-29 1991-01-28 Solid rapidly released medicament preparations containing dihydropyridines, and processes for their preparation

Country Status (1)

Country Link
US (1) USRE33963E (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266581A (en) * 1984-07-04 1993-11-30 Bayer Aktiengesellschaft Solid composition containing dihydropyridine, PVP and PVPP
WO1994023700A1 (en) * 1993-04-22 1994-10-27 Rijksuniversiteit Gent Laboratorium Voor Farmaceutische Technologie High release solid preparation, preparation and use thereof
US5478848A (en) * 1994-01-26 1995-12-26 Bayer Corporation Inhibition of arthritis by L-type calcium channel antagonists nimodipine, nisoldipine and nifedipine
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
US5900425A (en) 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
US20060257470A1 (en) * 2002-10-09 2006-11-16 Abbott Gmbh & Co. Kg Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4216155A (en) * 1977-07-15 1980-08-05 Ciba-Geigy Corporation Process for the preparation of novel benzopyrane derivatives
US4412986A (en) * 1977-06-07 1983-11-01 Yamanouchi Pharmaceutical Co. Ltd. Nifedipine-containing solid preparation composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4412986A (en) * 1977-06-07 1983-11-01 Yamanouchi Pharmaceutical Co. Ltd. Nifedipine-containing solid preparation composition
US4216155A (en) * 1977-07-15 1980-08-05 Ciba-Geigy Corporation Process for the preparation of novel benzopyrane derivatives

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, vol. 83 (1975), #209407w; Kramer et al.
Chemical Abstracts, vol. 83 (1975), 209407w; Kramer et al. *
Chemical Abstracts, vol. 90 (1979), #109987m; Kawata et al.
Chemical Abstracts, vol. 90 (1979), 109987m; Kawata et al. *
Chemical Abstracts, vol. 93 (1980), #53922d; Sugimoto et al.
Chemical Abstracts, vol. 93 (1980), 53922d; Sugimoto et al. *
Chemical Abstracts, vol. 96 (1982), #205448f; Hegasy et al.
Chemical Abstracts, vol. 96 (1982), 205448f; Hegasy et al. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266581A (en) * 1984-07-04 1993-11-30 Bayer Aktiengesellschaft Solid composition containing dihydropyridine, PVP and PVPP
WO1994023700A1 (en) * 1993-04-22 1994-10-27 Rijksuniversiteit Gent Laboratorium Voor Farmaceutische Technologie High release solid preparation, preparation and use thereof
US5478848A (en) * 1994-01-26 1995-12-26 Bayer Corporation Inhibition of arthritis by L-type calcium channel antagonists nimodipine, nisoldipine and nifedipine
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
US5900425A (en) 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
US20060257470A1 (en) * 2002-10-09 2006-11-16 Abbott Gmbh & Co. Kg Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier
US7846477B2 (en) 2002-10-09 2010-12-07 Abbott Gmbh & Co. Kg Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier

Similar Documents

Publication Publication Date Title
US4882144A (en) Solid, rapidly released medicament preparations containing dihydropyridines, and processes for their preparation
CA1280976C (en) Process for the preparation of solid nifedipine formulations of high bioavailability and with sustained effect, and formulations thusobtained
CA1146866A (en) Process for the production of sustained release pharmaceutical composition of solid medical material
US5015479A (en) Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US5972381A (en) Solid solution of an antifungal agent with enhanced bioavailability
US6383517B1 (en) Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
EP0232155A2 (en) Drug delivery system
EP0001247A1 (en) Pharmaceutical preparation containing nifedipine and a method for producing the same.
KR920006908B1 (en) Process for the preparation of solid drug containing dihydropyridine
JP2000514057A (en) Solid solution of antifungal agent with enhanced bioavailability
CA2216277C (en) Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance
CA2253769C (en) Pharmaceutical compositions comprising fenofibrate
US5445830A (en) Highly absorbable pharmaceutical composition
WO1989002738A1 (en) Sustained-release nifedipine formulation
USRE33963E (en) Solid rapidly released medicament preparations containing dihydropyridines, and processes for their preparation
JP3110794B2 (en) Preparation containing 1,4-dihydropyridine derivative
EP0371471A1 (en) Readily absorbable drug formulation of NB-818
EP0410422B1 (en) A highly absorbable pharmaceutical composition
JPH0338248B2 (en)
US5266581A (en) Solid composition containing dihydropyridine, PVP and PVPP
US8062664B2 (en) Process for preparing formulations of lipid-regulating drugs
KR880001558B1 (en) Processes for the production of solid rapidly released medicament preparations containing dihydropyridines
JPH04159222A (en) Production of solid preparation for oral administration
EP0487335A1 (en) Pharmaceutical dosage forms of dihydropyridines
JP5134818B2 (en) Method for the manufacture of lipid controlled drug formulations

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: BAYER HEALTHCARE AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER AKTIENGESELLSCHAFT;REEL/FRAME:016182/0190

Effective date: 20050307

AS Assignment

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:023148/0924

Effective date: 20090109

AS Assignment

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY

Free format text: A CHANGE OF NAME WAS RECORDED ON AUGUST 28, 2009 AT REEL/FRAME 023148/0924. THE ADDRESS SHOULD ALSO HAVE BEEN CHANGE FROM LEVERKUSEN GERMANY 51368 TO BERLIN, GERMANY 13353;ASSIGNOR:BAYER SCHERING PHARMA AKTIENGESELLSCHAFT;REEL/FRAME:024973/0737

Effective date: 20090105